S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
TSLA   901.00 (+0.18%)
T   38.55 (-0.16%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
TSLA   901.00 (+0.18%)
T   38.55 (-0.16%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
TSLA   901.00 (+0.18%)
T   38.55 (-0.16%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
S&P 500   3,337.75 (-1.05%)
DOW   28,992.41 (-0.78%)
QQQ   230.27 (-1.92%)
FB   210.18 (-2.05%)
MSFT   178.59 (-3.16%)
GOOGL   1,483.46 (-2.21%)
AMZN   2,095.97 (-2.65%)
NVDA   294.07 (-4.74%)
BABA   212.59 (-2.50%)
MU   56.99 (-3.41%)
TSLA   901.00 (+0.18%)
T   38.55 (-0.16%)
F   7.89 (-1.74%)
NFLX   380.07 (-1.54%)
PRI   132.33 (-2.98%)
BAC   34.36 (-1.41%)
Log in

NASDAQ:MEIP - MEI Pharma Stock Price, Forecast & News

$2.37
-0.02 (-0.84 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
$2.25
Now: $2.37
$2.42
50-Day Range
$2.04
MA: $2.30
$2.55
52-Week Range
$1.44
Now: $2.37
$3.41
Volume363,583 shs
Average Volume424,605 shs
Market Capitalization$251.22 million
P/E RatioN/A
Dividend YieldN/A
Beta1.73
MEI Pharma, Inc, a pharmaceutical company, focuses on the clinical development of novel therapies for the treatment of cancer. The company's clinical drug candidate includes Pracinostat, an oral available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer; and Voruciclib, an oral cyclin-dependent kinase inhibitor. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MEIP
Previous SymbolNASDAQ:MSHL
CUSIPN/A
Phone858-369-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.91 million
Book Value$0.73 per share

Profitability

Net Income$-16,820,000.00
Net Margins-825.55%

Miscellaneous

Employees32
Market Cap$251.22 million
Next Earnings Date5/14/2020 (Estimated)
OptionableOptionable

Receive MEIP News and Ratings via Email

Sign-up to receive the latest news and ratings for MEIP and its competitors with MarketBeat's FREE daily newsletter.


MEI Pharma (NASDAQ:MEIP) Frequently Asked Questions

What is MEI Pharma's stock symbol?

MEI Pharma trades on the NASDAQ under the ticker symbol "MEIP."

How were MEI Pharma's earnings last quarter?

MEI Pharma Inc (NASDAQ:MEIP) announced its quarterly earnings results on Thursday, February, 6th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.11. The business had revenue of $1.01 million for the quarter, compared to analysts' expectations of $1.24 million. MEI Pharma had a negative return on equity of 70.99% and a negative net margin of 825.55%. View MEI Pharma's Earnings History.

When is MEI Pharma's next earnings date?

MEI Pharma is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for MEI Pharma.

What price target have analysts set for MEIP?

2 brokerages have issued 1-year price objectives for MEI Pharma's stock. Their forecasts range from $10.00 to $10.00. On average, they anticipate MEI Pharma's share price to reach $10.00 in the next year. This suggests a possible upside of 321.9% from the stock's current price. View Analyst Price Targets for MEI Pharma.

What is the consensus analysts' recommendation for MEI Pharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MEI Pharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MEI Pharma.

Has MEI Pharma been receiving favorable news coverage?

Press coverage about MEIP stock has been trending somewhat negative this week, InfoTrie reports. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. MEI Pharma earned a news sentiment score of -1.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the company's share price in the near term. View News Stories for MEI Pharma.

Are investors shorting MEI Pharma?

MEI Pharma saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 367,900 shares, an increase of 25.2% from the December 31st total of 293,800 shares. Based on an average daily trading volume, of 419,200 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.6% of the company's stock are short sold. View MEI Pharma's Current Options Chain.

Who are some of MEI Pharma's key competitors?

What other stocks do shareholders of MEI Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MEI Pharma investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Opko Health (OPK), Actinium Pharmaceuticals (ATNM), Catalyst Pharmaceuticals (CPRX), Ocular Therapeutix (OCUL) and Geron (GERN).

Who are MEI Pharma's key executives?

MEI Pharma's management team includes the folowing people:
  • Dr. Daniel P. Gold, CEO, Pres & Director (Age 65)
  • Mr. Brian G. Drazba CPA, Sec. & CFO (Age 58)
  • Mr. David M. Urso Esq., J.D., COO, Sr. VP of Corp. Devel. & Gen. Counsel (Age 55)
  • Dr. Robert D. Mass M.D., Chief Medical Officer (Age 65)
  • Mr. David A. Walsey, VP of IR & Corp. Communications

Who are MEI Pharma's major shareholders?

MEI Pharma's stock is owned by many different of institutional and retail investors. Top institutional investors include NEA Management Company LLC (8.38%), BVF Inc. IL (5.04%), Renaissance Technologies LLC (2.82%), State Street Corp (1.17%), Point72 Asset Management L.P. (0.80%) and Geode Capital Management LLC (0.74%). Company insiders that own MEI Pharma stock include Brian G Drazba, Christine Anna White, Daniel P Phd Gold, David M Urso and Thomas C Reynolds. View Institutional Ownership Trends for MEI Pharma.

Which institutional investors are selling MEI Pharma stock?

MEIP stock was sold by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Oxford Asset Management LLP, New York State Common Retirement Fund and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for MEI Pharma.

Which institutional investors are buying MEI Pharma stock?

MEIP stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, NEA Management Company LLC, Point72 Asset Management L.P., Geode Capital Management LLC, Renaissance Technologies LLC, Panagora Asset Management Inc., State Street Corp and DAVENPORT & Co LLC. Company insiders that have bought MEI Pharma stock in the last two years include Brian G Drazba, Christine Anna White, Daniel P Phd Gold and Thomas C Reynolds. View Insider Buying and Selling for MEI Pharma.

How do I buy shares of MEI Pharma?

Shares of MEIP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is MEI Pharma's stock price today?

One share of MEIP stock can currently be purchased for approximately $2.37.

How big of a company is MEI Pharma?

MEI Pharma has a market capitalization of $251.22 million and generates $4.91 million in revenue each year. The company earns $-16,820,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. MEI Pharma employs 32 workers across the globe.View Additional Information About MEI Pharma.

What is MEI Pharma's official website?

The official website for MEI Pharma is http://www.meipharma.com/.

How can I contact MEI Pharma?

MEI Pharma's mailing address is 3611 VALLEY CENTER DRIVE, SAN DIEGO CA, 92130. The company can be reached via phone at 858-369-7100 or via email at [email protected]


MarketBeat Community Rating for MEI Pharma (NASDAQ MEIP)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  325 (Vote Outperform)
Underperform Votes:  259 (Vote Underperform)
Total Votes:  584
MarketBeat's community ratings are surveys of what our community members think about MEI Pharma and other stocks. Vote "Outperform" if you believe MEIP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MEIP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/21/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel